Premium
Diagnostic significance of antinuclear antibodies in neurologic patients
Author(s) -
Michielsens B.,
Walravens M.,
Vermylen J.,
Carton H.
Publication year - 1991
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1991.tb04916.x
Subject(s) - anti nuclear antibody , medicine , lupus anticoagulant , connective tissue disease , ctd , prospective cohort study , mixed connective tissue disease , clinical significance , undifferentiated connective tissue disease , systemic disease , retrospective cohort study , disease , autoimmune disease , pathology , autoantibody , antibody , immunology , thrombosis , oceanography , geology
In a combined retrospective and prospective study, we tried to define the prevalence of antinuclear antibodies (ANA) and its clinical relevance in neurological patients. Three hundred twenty‐seven neurological patients who had ANA determined because of suspicion of connective tissue disease (CTD), were retrospectively studied. Thirty (9.2%) were ANA positive, 20 (66%) of whom had CTD. of 327 consecutively admitted patients, prospectively studied, 18 (5.5%) were ANA positive, 5 (28%) of whom had evidence of CTD. Systemic lupus erythematosus (SLE) was the most frequently diagnosed CTD. In a prospective study of 48 multiple sclerosis (MS) patients, only 1 had detectable ANA at a dilution of 1:40. Lupus anticoagulans (LA) was prospectively detected in 2 patients but was not associated with a vascular or autoimmune systemic disease.